HRP20110892T1 - Policiklični derivati indazola koji su inhibitori erk - Google Patents

Policiklični derivati indazola koji su inhibitori erk Download PDF

Info

Publication number: HRP20110892T1
Authority: HR; Croatia
Prior art keywords: substituted; group; image; pharmaceutically acceptable; alkyl
Prior art date: 2005-12-13

Application number

HR20110892T

Other languages

English (en)

Croatian (hr)

Inventor

Cooper Alan

Deng Yongqi

W. Jr. Shipps Gerald

Shih Neng-Yang

Zhu Hugh

Sun Robert

Kelly Joseph

Doll Ronald

Nan Yang

Wang Tong

Desai Jagdish

Wang James

Dong Youhao

S. Madison Vincent

Xiao Li

Hruza Alan

Arshad Siddiqui M.

Samatar Ahmed

Paliwal Sunil

Tsui Hon-Chung

A. Celebi Azim

Wu Yiji

Babu Boga Sobhana

Original Assignee

Schering Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-13

Filing date

2011-11-30

Publication date

2011-12-31

2011-11-30 Application filed by Schering Corporation filed Critical Schering Corporation

2011-12-31 Publication of HRP20110892T1 publication Critical patent/HRP20110892T1/hr

Links

-1 Polycyclic indazole derivatives Chemical class 0.000 title claims 2
239000012824 ERK inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract 82
150000003839 salts Chemical class 0.000 claims abstract 70
125000000217 alkyl group Chemical group 0.000 claims abstract 43
125000001072 heteroaryl group Chemical group 0.000 claims abstract 24
125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 19
125000001424 substituent group Chemical group 0.000 claims abstract 19
125000000753 cycloalkyl group Chemical group 0.000 claims abstract 18
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 15
125000003118 aryl group Chemical group 0.000 claims abstract 13
125000005843 halogen group Chemical group 0.000 claims abstract 13
125000000547 substituted alkyl group Chemical group 0.000 claims abstract 11
125000003342 alkenyl group Chemical group 0.000 claims abstract 9
125000005346 substituted cycloalkyl group Chemical group 0.000 claims abstract 9
125000003710 aryl alkyl group Chemical group 0.000 claims abstract 8
125000003107 substituted aryl group Chemical group 0.000 claims abstract 8
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 4
125000004366 heterocycloalkenyl group Chemical group 0.000 claims abstract 4
125000000304 alkynyl group Chemical group 0.000 claims abstract 2
125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
239000003814 drug Substances 0.000 claims 75
229940079593 drug Drugs 0.000 claims 58
238000004519 manufacturing process Methods 0.000 claims 47
239000002246 antineoplastic agent Substances 0.000 claims 25
229940127089 cytotoxic agent Drugs 0.000 claims 25
206010028980 Neoplasm Diseases 0.000 claims 13
201000011510 cancer Diseases 0.000 claims 12
125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 11
239000003112 inhibitor Substances 0.000 claims 10
206010006187 Breast cancer Diseases 0.000 claims 9
208000026310 Breast neoplasm Diseases 0.000 claims 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
150000003384 small molecules Chemical class 0.000 claims 6
206010009944 Colon cancer Diseases 0.000 claims 5
206010058467 Lung neoplasm malignant Diseases 0.000 claims 5
206010033128 Ovarian cancer Diseases 0.000 claims 5
206010061535 Ovarian neoplasm Diseases 0.000 claims 5
206010061902 Pancreatic neoplasm Diseases 0.000 claims 5
208000024770 Thyroid neoplasm Diseases 0.000 claims 5
230000001419 dependent effect Effects 0.000 claims 5
201000005202 lung cancer Diseases 0.000 claims 5
208000020816 lung neoplasm Diseases 0.000 claims 5
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 5
201000001441 melanoma Diseases 0.000 claims 5
201000002528 pancreatic cancer Diseases 0.000 claims 5
208000008443 pancreatic carcinoma Diseases 0.000 claims 5
201000002510 thyroid cancer Diseases 0.000 claims 5
208000003174 Brain Neoplasms Diseases 0.000 claims 4
208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
125000002877 alkyl aryl group Chemical group 0.000 claims 4
239000013059 antihormonal agent Substances 0.000 claims 4
229940088597 hormone Drugs 0.000 claims 4
239000005556 hormone Substances 0.000 claims 4
206010005003 Bladder cancer Diseases 0.000 claims 3
208000034578 Multiple myelomas Diseases 0.000 claims 3
201000003793 Myelodysplastic syndrome Diseases 0.000 claims 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
206010035226 Plasma cell myeloma Diseases 0.000 claims 3
206010060862 Prostate cancer Diseases 0.000 claims 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
208000025113 myeloid leukemia Diseases 0.000 claims 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
201000005112 urinary bladder cancer Diseases 0.000 claims 3
208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 claims 2
108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
125000005015 aryl alkynyl group Chemical group 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 2
201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
125000005312 heteroarylalkynyl group Chemical group 0.000 claims 2
229940043355 kinase inhibitor Drugs 0.000 claims 2
239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
230000002265 prevention Effects 0.000 claims 2
239000000333 selective estrogen receptor modulator Substances 0.000 claims 2
229940095743 selective estrogen receptor modulator Drugs 0.000 claims 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 2
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 claims 1
206010002240 Anaplastic thyroid cancer Diseases 0.000 claims 1
108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims 1
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims 1
102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 1
101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 1
102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims 1
101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 claims 1
102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
101800003838 Epidermal growth factor Proteins 0.000 claims 1
229940102550 Estrogen receptor antagonist Drugs 0.000 claims 1
229940123414 Folate antagonist Drugs 0.000 claims 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 1
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
229940124647 MEK inhibitor Drugs 0.000 claims 1
206010029260 Neuroblastoma Diseases 0.000 claims 1
108091000080 Phosphotransferase Proteins 0.000 claims 1
108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 1
102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 1
206010039491 Sarcoma Diseases 0.000 claims 1
229940123237 Taxane Drugs 0.000 claims 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
229940122803 Vinca alkaloid Drugs 0.000 claims 1
229940100198 alkylating agent Drugs 0.000 claims 1
239000002168 alkylating agent Substances 0.000 claims 1
239000004037 angiogenesis inhibitor Substances 0.000 claims 1
229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
229940045799 anthracyclines and related substance Drugs 0.000 claims 1
230000000259 anti-tumor effect Effects 0.000 claims 1
239000003124 biologic agent Substances 0.000 claims 1
229910052794 bromium Inorganic materials 0.000 claims 1
230000022131 cell cycle Effects 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
229910052801 chlorine Inorganic materials 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 claims 1
239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229940116977 epidermal growth factor Drugs 0.000 claims 1
229930013356 epothilone Natural products 0.000 claims 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims 1
229910052731 fluorine Inorganic materials 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
201000010536 head and neck cancer Diseases 0.000 claims 1
208000014829 head and neck neoplasm Diseases 0.000 claims 1
206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
150000003949 imides Chemical class 0.000 claims 1
102000006495 integrins Human genes 0.000 claims 1
108010044426 integrins Proteins 0.000 claims 1
150000003833 nucleoside derivatives Chemical class 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
102000020233 phosphotransferase Human genes 0.000 claims 1
229910052697 platinum Inorganic materials 0.000 claims 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 1
238000001959 radiotherapy Methods 0.000 claims 1
108010077182 raf Kinases Proteins 0.000 claims 1
102000009929 raf Kinases Human genes 0.000 claims 1
230000019491 signal transduction Effects 0.000 claims 1
125000005017 substituted alkenyl group Chemical group 0.000 claims 1
229960004964 temozolomide Drugs 0.000 claims 1
229960003433 thalidomide Drugs 0.000 claims 1
208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 claims 1
229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
125000001153 fluoro group Chemical group F* 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

HR20110892T 2005-12-13 2011-11-30 Policiklični derivati indazola koji su inhibitori erk HRP20110892T1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74985605P	2005-12-13	2005-12-13
PCT/US2006/046959 WO2007070398A1 (en)	2005-12-13	2006-12-11	Polycyclic indazole derivatives that are erk inhibitors

Publications (1)

Publication Number	Publication Date
HRP20110892T1 true HRP20110892T1 (hr)	2011-12-31

Family

ID=37969564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20110892T HRP20110892T1 (hr)	2005-12-13	2011-11-30	Policiklični derivati indazola koji su inhibitori erk

Country Status (29)

Country	Link
US (1)	US20070191604A1 (ru)
EP (1)	EP1966151B1 (ru)
JP (1)	JP4881957B2 (ru)
KR (1)	KR101417136B1 (ru)
CN (1)	CN101370784B (ru)
AR (1)	AR056891A1 (ru)
AT (1)	ATE527240T1 (ru)
AU (1)	AU2006326616B2 (ru)
BR (1)	BRPI0619823B8 (ru)
CA (1)	CA2633023C (ru)
CY (1)	CY1112760T1 (ru)
DK (1)	DK1966151T3 (ru)
EC (1)	ECSP088550A (ru)
ES (1)	ES2372976T3 (ru)
HK (1)	HK1114851A1 (ru)
HR (1)	HRP20110892T1 (ru)
IL (1)	IL192034A (ru)
MY (1)	MY149430A (ru)
NO (1)	NO341831B1 (ru)
NZ (1)	NZ569087A (ru)
PE (2)	PE20100562A1 (ru)
PL (1)	PL1966151T3 (ru)
PT (1)	PT1966151E (ru)
RS (1)	RS51981B (ru)
RU (1)	RU2442778C9 (ru)
SI (1)	SI1966151T1 (ru)
TW (1)	TWI344466B (ru)
WO (1)	WO2007070398A1 (ru)
ZA (1)	ZA200805525B (ru)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
WO2017058007A1 (en)	2015-10-01	2017-04-06	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
WO2017099591A1 (en)	2015-12-07	2017-06-15	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en)	2016-05-24	2017-11-30	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8546404B2 (en) *	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
US7807672B2 (en) *	2006-02-16	2010-10-05	Schering Corporation	Compounds that are ERK inhibitors
US7884107B2 (en)	2006-06-30	2011-02-08	Merck	Substituted piperidines that increase P53 activity and the uses thereof
NZ581698A (en) *	2007-06-05	2012-09-28	Merck Sharp & Dohme	Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
AR067354A1 (es)	2007-06-29	2009-10-07	Sunesis Pharmaceuticals Inc	Compuestos utiles como inhibidores de la raf quinasa
WO2009073513A1 (en) *	2007-11-30	2009-06-11	Schering Corporation	Braf biomarkers
ES2556353T3 (es) *	2008-02-21	2016-01-15	Merck Sharp & Dohme Corp.	Compuestos que son inhibidores de las ERK
TW200940539A (en)	2008-02-29	2009-10-01	Array Biopharma Inc	RAF inhibitor compounds and methods of use thereof
WO2009137649A2 (en) *	2008-05-07	2009-11-12	The Trustees Of The University Of Pennsylvania	Methods for treating thyroid cancer
US9229008B2 (en)	2008-08-19	2016-01-05	Merck Sharp & Dohme Corp.	IL-8 level as a determinant of responsivity of a cancer to treatment
WO2010021978A2 (en) *	2008-08-19	2010-02-25	Schering Corporation	Il-8 biomarker
US8609675B2 (en)	2009-07-02	2013-12-17	Merck Sharp & Dohme Corp.	Fused Tricyclic Compounds as novel mTOR inhibitors
AU2010300925A1 (en)	2009-09-30	2012-03-29	Merck Sharp & Dohme Corp.	Novel compounds that are ERK inhibitors
CN104945382B (zh)	2009-10-14	2020-02-07	默沙东公司	提高p53活性的取代的哌啶和其用途
WO2011123937A1 (en) *	2010-04-06	2011-10-13	University Health Network	Kinase inhibitors and method of treating cancer with same
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
WO2012015932A2 (en) *	2010-07-27	2012-02-02	Protexer, Inc.	Shoe cover removal apparatus
EP2608669B1 (en)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) *	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
WO2012078777A1 (en) *	2010-12-09	2012-06-14	Amgen Inc.	Bicyclic compounds as pim inhibitors
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
EP2688886A1 (en)	2011-03-22	2014-01-29	Amgen Inc.	Azole compounds as pim inhibitors
US20140045847A1 (en)	2011-04-21	2014-02-13	Piramal Enterprises Limited	Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US8901142B2 (en)	2011-07-26	2014-12-02	Merck Sharp & Dohme Corp.	Fused tricyclic compounds as mTOR inhibitors
WO2013062923A1 (en)	2011-10-28	2013-05-02	Merck Sharp & Dohme Corp.	MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US9062071B2 (en)	2011-12-21	2015-06-23	Merck Sharp & Dohme Corp.	Substituted piperidines as HDM2 inhibitors
ITMI20120135A1 (it) *	2012-02-02	2013-08-03	Diab Int Ab	Procedimento per la produzione di schiume di pet e schiume di pet ottenute con questo procedimento
WO2013169858A1 (en)	2012-05-08	2013-11-14	The Broad Institute, Inc.	Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103450163B (zh) *	2012-05-29	2017-06-23	中国医学科学院药物研究所	吲唑类化合物、其制备方法及其药物用途
ES2612885T3 (es)	2012-09-19	2017-05-19	Novartis Ag	Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa
MX2015004041A (es) *	2012-09-28	2015-07-06	Merck Sharp & Dohme	Compuestos novedosos que son inhibidores de erk.
CA2895504A1 (en)	2012-12-20	2014-06-26	Merck Sharp & Dohme Corp.	Substituted imidazopyridines as hdm2 inhibitors
HUE039306T2 (hu)	2013-11-01	2018-12-28	Novartis Ag	Kináz inhibitor aminoheteroaril-benzamidok
WO2016095089A1 (en)	2014-12-15	2016-06-23	Merck Sharp & Dohme Corp.	Erk inhibitors
WO2016095088A1 (en) *	2014-12-15	2016-06-23	Merck Sharp & Dohme Corp.	Erk inhibitors
CA3001799A1 (en)	2015-10-21	2017-04-27	Otsuka Pharmaceutical Co., Ltd.	Benzolactam compounds as protein kinase inhibitors
EP3426637B1 (en)	2016-03-11	2022-02-09	Angel Pharmaceutical Co., Ltd.	Compounds and methods for modulating bruton's tyrosine kinase
KR20190075931A (ko) *	2016-10-05	2019-07-01	제노 로얄티즈 앤 마일스톤즈, 엘엘씨	스피로 고리 화합물
GB201706327D0 (en)	2017-04-20	2017-06-07	Otsuka Pharma Co Ltd	A pharmaceutical compound
US10508113B2 (en)	2018-03-12	2019-12-17	Abbvie Inc.	Inhibitors of tyrosine kinase 2 mediated signaling
CN114605329B (zh) *	2022-03-28	2024-01-26	河南中医药大学	取代的吲唑甲酰胺或取代的氮杂吲唑甲酰胺类flt3抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9213077D0 (en)	1992-06-19	1992-08-05	Erba Carlo Spa	Polymerbound taxol derivatives
SK14082001A3 (sk) *	2000-02-05	2002-03-05	Vertex Pharmaceuticals Incorporated	Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje
US6897231B2 (en)	2000-07-31	2005-05-24	Signal Pharmaceuticals, Inc.	Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MY130778A (en) *	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
RU2378259C2 (ru) *	2002-09-05	2010-01-10	Авентис Фарма С.А.	Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции

2006
- 2006-12-11 PL PL06845064T patent/PL1966151T3/pl unknown
- 2006-12-11 NZ NZ569087A patent/NZ569087A/en not_active IP Right Cessation
- 2006-12-11 AU AU2006326616A patent/AU2006326616B2/en active Active
- 2006-12-11 JP JP2008545685A patent/JP4881957B2/ja active Active
- 2006-12-11 ES ES06845064T patent/ES2372976T3/es active Active
- 2006-12-11 KR KR1020087016729A patent/KR101417136B1/ko active IP Right Grant
- 2006-12-11 SI SI200631221T patent/SI1966151T1/sl unknown
- 2006-12-11 RS RS20110516A patent/RS51981B/en unknown
- 2006-12-11 CA CA2633023A patent/CA2633023C/en active Active
- 2006-12-11 CN CN2006800527776A patent/CN101370784B/zh active Active
- 2006-12-11 BR BRPI0619823A patent/BRPI0619823B8/pt active IP Right Grant
- 2006-12-11 DK DK06845064.2T patent/DK1966151T3/da active
- 2006-12-11 RU RU2008128119/04A patent/RU2442778C9/ru active
- 2006-12-11 EP EP06845064A patent/EP1966151B1/en active Active
- 2006-12-11 US US11/636,954 patent/US20070191604A1/en not_active Abandoned
- 2006-12-11 PT PT06845064T patent/PT1966151E/pt unknown
- 2006-12-11 WO PCT/US2006/046959 patent/WO2007070398A1/en active Application Filing
- 2006-12-11 AT AT06845064T patent/ATE527240T1/de active
- 2006-12-11 MY MYPI20082076A patent/MY149430A/en unknown
- 2006-12-12 AR ARP060105474A patent/AR056891A1/es active IP Right Grant
- 2006-12-12 PE PE2010000279A patent/PE20100562A1/es not_active Application Discontinuation
- 2006-12-12 TW TW095146375A patent/TWI344466B/zh not_active IP Right Cessation
- 2006-12-12 PE PE2006001592A patent/PE20071095A1/es active IP Right Grant
2008
- 2008-06-10 IL IL192034A patent/IL192034A/en active IP Right Grant
- 2008-06-13 EC EC2008008550A patent/ECSP088550A/es unknown
- 2008-06-24 ZA ZA200805525A patent/ZA200805525B/xx unknown
- 2008-07-11 NO NO20083114A patent/NO341831B1/no not_active IP Right Cessation
- 2008-09-12 HK HK08110160.5A patent/HK1114851A1/xx not_active IP Right Cessation
2011
- 2011-11-30 HR HR20110892T patent/HRP20110892T1/hr unknown
2012
- 2012-01-04 CY CY20121100006T patent/CY1112760T1/el unknown

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
WO2017058007A1 (en)	2015-10-01	2017-04-06	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma
WO2017099591A1 (en)	2015-12-07	2017-06-15	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Treatment of inhibitor resistant braf-mutant cancers
WO2017204626A1 (en)	2016-05-24	2017-11-30	Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis	Combination therapy - combined map2k4/map3k1 and mek/erk inhibition

Also Published As

Publication number	Publication date
NO20083114L (no)	2008-09-12
CA2633023C (en)	2015-11-24
ZA200805525B (en)	2009-11-25
NZ569087A (en)	2011-09-30
RU2442778C2 (ru)	2012-02-20
US20070191604A1 (en)	2007-08-16
SI1966151T1 (sl)	2012-02-29
CY1112760T1 (el)	2016-02-10
TW200732324A (en)	2007-09-01
CN101370784A (zh)	2009-02-18
KR20080085018A (ko)	2008-09-22
BRPI0619823B1 (pt)	2020-11-17
ES2372976T3 (es)	2012-01-30
ECSP088550A (es)	2008-07-30
JP4881957B2 (ja)	2012-02-22
PT1966151E (pt)	2011-12-20
PE20100562A1 (es)	2010-08-20
BRPI0619823A2 (pt)	2011-11-08
AU2006326616A1 (en)	2007-06-21
CN101370784B (zh)	2012-10-10
AR056891A1 (es)	2007-10-31
KR101417136B1 (ko)	2014-08-07
DK1966151T3 (da)	2012-01-30
RU2008128119A (ru)	2010-01-20
BRPI0619823B8 (pt)	2021-05-25
IL192034A0 (en)	2008-12-29
WO2007070398A1 (en)	2007-06-21
RU2442778C9 (ru)	2012-08-10
IL192034A (en)	2014-08-31
TWI344466B (en)	2011-07-01
PE20071095A1 (es)	2007-11-19
NO341831B1 (no)	2018-01-29
AU2006326616B2 (en)	2012-09-06
RS51981B (en)	2012-02-29
PL1966151T3 (pl)	2012-02-29
HK1114851A1 (en)	2008-11-14
JP2009519338A (ja)	2009-05-14
CA2633023A1 (en)	2007-06-21
MY149430A (en)	2013-08-30
BRPI0619823A8 (pt)	2019-01-22
EP1966151A1 (en)	2008-09-10
ATE527240T1 (de)	2011-10-15
EP1966151B1 (en)	2011-10-05

Publication	Publication Date	Title
HRP20110892T1 (hr)	2011-12-31	Policiklični derivati indazola koji su inhibitori erk
ES2558777T3 (es)	2016-02-08	(R)-(E)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1H-indazol-3-il)vinil)-1H-pirazol-1-il)etanol cristalino y su uso como inhibidor de FGFR
JP2010505859A (ja)	2010-02-25	タンパク質キナーゼ阻害剤およびそれを使用するための方法
JP5997252B2 (ja)	2016-09-28	プロテインキナーゼ阻害剤
R Prakash et al.	2012	Indolinones as promising scaffold as kinase inhibitors: a review
ES2345629T3 (es)	2010-09-28	Derivados de pirrolopiridina como inhibidores de proteina quinasas.
RU2010138635A (ru)	2012-03-27	Соединения, которые являются ингибиторами erk
RU2009148867A (ru)	2011-07-20	Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака
ES2576497T3 (es)	2016-07-07	Compuesto de piperidina novedoso o sal del mismo
HRP20151410T1 (hr)	2016-01-15	Derivati pikolinamida kao inhibitori kinaze
EA200800478A1 (ru)	2008-08-29	Макроциклические ингибиторы вируса гепатита с
HRP20140516T1 (hr)	2014-07-04	Farmaceutski spojevi
SI2684880T1 (en)	2018-08-31	DERIVAT DISPIROPYROLIDINE
ES2914072T3 (es)	2022-06-07	Sal de derivado de piridina monocíclico y su cristal
HRP20121023T1 (hr)	2013-01-31	Inhibitori za iap
PE20090493A1 (es)	2009-05-27	DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
BRPI0519288A2 (pt)	2009-01-06	compostos heterocÍclicos como antagonistas de ccr2b
BR112012015248B1 (pt)	2022-01-04	Composto
RU2009126576A (ru)	2011-01-20	Конденсированное гетероциклическое соединение
KR20090129488A (ko)	2009-12-16	야누스 키나아제의 억제제로서 유용한 ｎ-헤테로사이클릭 화합물
AR046170A1 (es)	2005-11-30	Derivados de pirimidin-2-amina y su uso como antagonistas del receptor de adenosina a 2b
KR20170036095A (ko)	2017-03-31	Smac 모방체로서의 6-알키닐 피리딘 유도체
Winfield et al.	2018	Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition
EP3856735A1 (en)	2021-08-04	Fused bicyclic heterocycles as thereapeutic agents
Liu et al.	2014	Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors

HRP20110892T1 - Policiklični derivati indazola koji su inhibitori erk - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=37969564

Family Applications (1)

Country Status (29)

Cited By (8)

Families Citing this family (41)

Family Cites Families (5)

Cited By (8)

Also Published As

Similar Documents